We are live on ! Find out more
CYTO

Altamira Therapeutics Ltd
CYTO

Delisted

CYTO was delisted on the 19th of December, 2024.

Back to rankings

8 hedge funds and large institutions have $31.3M invested in Altamira Therapeutics Ltd in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

20% less funds holding

Funds holding: 10 → 8 (-2)

37% less capital invested

Capital invested by funds: $50M → $31.3M (-$18.7M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1K

Holders
8
Holders Change
-2
Holders Change %
-20%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
3
Closed
2
Calls
–
Puts
$1K
Net Calls
-$1K
Net Calls Change
-$1K

Top Buyers

Rank Fund Capital Flow
1
RSCM
Rock Springs Capital Management
Maryland
+$3.56M

Top Sellers

Rank Fund Capital Flow
1
TCM
Tekla Capital Management
Massachusetts
-$2.14M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.02M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$712K
4
HCM
Harvey Capital Management
Florida
-$356K
5
OM
Opaleye Management
Massachusetts
-$356K
Name Holding Trade Value Shares
Change 		Change in
Stake
WA
1
Wasatch Advisors
Utah
$9.68M – – –
BG
2
Bellevue Group
Switzerland
$7.9M +$9.61M +27 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$5.65M -$712K -2 -10%
TCM
4
Tekla Capital Management
Massachusetts
$3.04M -$2.14M -6 -38%
RSCM
5
Rock Springs Capital Management
Maryland
$2.87M +$3.56M +10 New
OM
6
Opaleye Management
Massachusetts
$1.24M -$356K -1 -20%
TAM
7
Tocqueville Asset Management
New York
$273K – – –
KeyBank National Association
8
KeyBank National Association
Ohio
$159K – – –
HCM
9
Harvey Capital Management
Florida
$136K -$356K -1 Closed
TC
10
TFS Capital
Pennsylvania
$118K – – –
Goldman Sachs
11
Goldman Sachs
New York
$90K – – –
ZIM
12
Zacks Investment Management
Illinois
$86K – – –
VKH
13
Virtu KCG Holdings
New York
$46K – – –
AC
14
Amici Capital
New York
$36K – – –
AIG
15
American International Group
New York
$13K – – –
Citigroup
16
Citigroup
New York
$7K – – –
JP Morgan Chase
17
JP Morgan Chase
New York
$5K – – –
Morgan Stanley
18
Morgan Stanley
New York
$2K – – –
HI
19
Hudock Inc
Pennsylvania
$1K – – –
Simplex Trading
20
Simplex Trading
Illinois
$1K – – –
TRCT
21
Tower Research Capital (TRC)
New York
$1K – – –
Geode Capital Management
22
Geode Capital Management
Massachusetts
$56 – – –
Alyeska Investment Group
23
Alyeska Investment Group
Illinois
– -$1.02M -3 Closed
MLM
24
Mount Lucas Management
Pennsylvania
– -$15K – –
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
– -$59K – –
1
2

CYTO Hedge Fund Activity: Q1 2016 in Review

8 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q1 2016, worth a combined $31.3M — down 37% from $50M a quarter earlier.

Fund positioning in CYTO was balanced in Q1 2016: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 3 trimmed.

The largest buyer was Rock Springs Capital Management, opening a new position worth an estimated $3.56M. The largest seller was Tekla Capital Management, cutting an estimated $2.14M.

  • 8 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q1 2016, down from 10 in Q4 2015.
  • Funds reported $31.3M of Altamira Therapeutics Ltd stock for Q1 2016, down 37% quarter-over-quarter.
  • 2 funds opened new Altamira Therapeutics Ltd positions in Q1 2016 and 2 closed out, a net change of 0 holders.
  • The largest Altamira Therapeutics Ltd buyer in Q1 2016 was Rock Springs Capital Management, an estimated $3.56M added.
  • The largest Altamira Therapeutics Ltd seller in Q1 2016 was Tekla Capital Management, an estimated $2.14M sold.

Based on aggregated 13F filings for Q1 2016.